# A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

> **NCT04744207** · PHASE2 · COMPLETED · sponsor: **Gesynta Pharma AB** · enrollment: 94 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** GS-248
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04744207
- **Lead sponsor:** Gesynta Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-29
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04744207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04744207, "A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04744207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*